Abstract
Hypercholesterolemia is a common disorder after heart transplantation and my be associated with the development of transplant coronary artery disease. 3-hydroxy 3-methylglutaryl coenzyme A reductase inhibitors (HMG CoA) are the most effective drugs to lower cholesterol level in transplant patients. However, interaction of immunosuppressants with HMG CoA inhibitors, which are metabolized by cytochrome P 450, increase incidence of skeletal muscle myopathy and rhabdomyolysis.
MeSH terms
-
Coronary Artery Disease / drug therapy*
-
Coronary Artery Disease / etiology
-
Cyclosporine / adverse effects*
-
Cytochrome P-450 Enzyme System / metabolism
-
Drug Interactions
-
Heart Transplantation / adverse effects*
-
Humans
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors / adverse effects
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
-
Hypercholesterolemia / drug therapy*
-
Hypercholesterolemia / etiology
-
Rhabdomyolysis / chemically induced*
Substances
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors
-
Cyclosporine
-
Cytochrome P-450 Enzyme System